# Fibroblast miR-486-3p suppresses bladder cancer via HER-2 in tissue and cell studies

- Published: 2026-11-11 13:59 UTC
- Section: Life & Health › Medicine
- Tags: miR-486-3p, bladder cancer, cancer-associated fibroblasts, HER-2, tumor microenvironment, single-cell RNA sequencing, zongertinib, PD-1 blockade, exosomal delivery, MDK-NCL axis
- URL: https://realtech.media/news/rt-e658ebe8cf645c1737cab5db_fibroblast_mir_486/

**Authors report that miR-486-3p, localized to cancer-associated fibroblasts, targets HER-2 in bladder cancer; low levels predicted resistance to PD-1/PD-L1 blockade.**

![Fibroblast miR-486-3p suppresses bladder cancer via HER-2 in tissue and cell studies](https://realtech.media/media/2026/11/0f336045ecbc13d5.jpg)
*http://www.scientificanimations.com/, Wikimedia Commons, CC BY-SA 4.0*

In a study published in Biology Direct in 2026, Li, Dong, Zhu, Sun, Zuo and Liu identified miR-486-3p as a suppressor of bladder cancer (BLCA) progression [1]. The microRNA is localized to cancer-associated fibroblasts (CAFs) and its expression pattern is consistent with exosomal delivery. The result comes from integrative single-cell and transcriptomic analyses [1].

CAFs are key stromal components of the tumor microenvironment, but their capacity to deliver tumor-suppressive signals had remained unclear. The authors describe miR-486-3p as part of a stromal-epithelial checkpoint that acts on the HER-2/MDK-NCL axis [1].

## miR-486-3p and HER-2 in bladder cancer

miR-486-3p was consistently downregulated in BLCA tissues and correlated with favorable overall survival. Its direct target, HER-2, was upregulated and linked to poor prognosis [1].

miR-486-3p bound the 3′-UTR of HER-2 mRNA directly. In cell experiments, reconstitution of HER-2 abrogated the tumor-suppressive effects of miR-486-3p on proliferation, migration, invasion and apoptosis [1].

Single-cell RNA sequencing of 58,982 cells localized HER-2 and related targets exclusively to malignant cell populations. Within them, the analysis resolved a HER-2-high subpopulation with hyper-proliferative expression signatures [1].

## Immunotherapy cohorts and inhibitor screening

In immunotherapy cohorts, low miR-486-3p or high HER-2 expression predicted immune-cold phenotypes and resistance to PD-1/PD-L1 blockade [1].

The authors also ran a computational screen for HER-2-directed agents. It identified zongertinib as a high-affinity HER-2 inhibitor with favorable pharmacokinetics [1]. This is a computational result; the source does not describe experimental testing of the compound in this work.

The authors conclude that the findings have implications for prognosis, immune evasion and HER-2-directed therapy [1]. The work rests on tissue data, cell assays, single-cell sequencing and computational analysis, and the delivery of miR-486-3p by exosomes is described as likely rather than shown directly.

## Sources

1. [Biology Direct](https://doi.org/10.1186/s13062-026-00981-3)
2. [bioengineer.org](https://bioengineer.org/fibroblast-microrna-suppresses-bladder-cancer-progression-by-targeting-her-2-axis)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-e658ebe8cf645c1737cab5db_fibroblast_mir_486/